Odinwell Valuation

Is ODIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ODIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ODIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ODIN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ODIN?

Key metric: As ODIN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ODIN. This is calculated by dividing ODIN's market cap by their current revenue.
What is ODIN's PS Ratio?
PS Ratio	14.8x
Sales	SEK 4.70m
Market Cap	SEK 71.92m

ODIN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.5x
Enterprise Value/EBITDA	-10.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ODIN's PS Ratio compare to its peers?

The above table shows the PS ratio for ODIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.2x
EPIS B Episurf Medical	7.7x	93.5%	SEK 96.0m
SDOS ScandiDos	1.5x	n/a	SEK 96.9m
DIGN Dignitana	1x	20.4%	SEK 91.8m
CRBX Carbiotix	10.3x	n/a	SEK 33.6m
ODIN Odinwell	14.8x	n/a	SEK 69.5m

Price-To-Sales vs Peers: ODIN is expensive based on its Price-To-Sales Ratio (14.8x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does ODIN's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

16 Companies	Price / Sales	Estimated Growth	Market Cap
GETI B Getinge	1.4x	5.7%	US$4.19b
EKTA B Elekta	1.4x	6.3%	US$2.27b
ARJO B Arjo	0.8x	3.7%	US$847.99m
ADDV A ADDvise Group	1.3x	8.5%	US$68.62m

16 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ODIN is expensive based on its Price-To-Sales Ratio (14.8x) compared to the Swedish Medical Equipment industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is ODIN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ODIN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ODIN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Iconovo

SEK 78.0m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 4.82

-4.4%

-45.5%

Arcoma

SEK 141.7m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.75

3.9%

50.3%

Dignitana

SEK 93.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.14

-7.3%

-47.9%